Imaging Contrast

Contrast agents are injected into patients to help enhance images to make it easier for radiologists distinguish specific areas of the body from surrounding tissues. The most commonly used agents are iodinated contrast dye for computed tomography (CT), interventional cath lab angiography, RF fluoroscopy, and in surgical OR procedures. MRI scans typically use gadolinium-based contrast agents. Ultrasound and echocardiography (cardiac ultrasound) imaging use contrast agents composed of microscopic bubbles to enhance images that otherwise would be suboptimal.

FDA approves expanded use of gadolinium-based imaging agent
Gadopiclenol is a macrocyclic high-relaxivity GBCA that contains less than half the amount of gadolinium that standard agents are formulated with.
Bayer: Aiding Customer Resilience Amid CT Disruption
U.S. Radiology departments navigating CT market challenges—supply disruptions and rising demand for contrast and delivery—need reliable partners. Hear Bayer leads explain how Bayer helps provide steady supply and innovations to support CT imaging and patient care.
New oral contrast agent helps spot 'previously impossible-to-detect' findings on CT
Experts involved in its development are confident the agent has the potential to overcome shortcomings associated with conventional oral agents currently on the market.
Prominent organizations endorse new contrast-enhanced ultrasound curriculum and training
The endorsement follows recent program updates, implemented following an expansion to the Scope of Practice and Clinical Standards for the Diagnostic Medical Sonographer.
New iron-based imaging agent significantly improves brain tumor visualization
Ferumoxytol is used primarily in medications that treat anemia, but the FDA recently cleared it for deployment in brain imaging as well.

The new MRI contrast agent gadopiclenol, sold under the trade names Elucirem and Vueway by Bracco and Guerbet, used 50% less gadolinium that current MRI agents. #RSNA22 #RSNA

FDA approves expanded use of gadolinium-based imaging agent

Gadopiclenol is a macrocyclic high-relaxivity GBCA that contains less than half the amount of gadolinium that standard agents are formulated with.

Bayer: Aiding Customer Resilience Amid CT Disruption

Sponsored by Bayer

U.S. Radiology departments navigating CT market challenges—supply disruptions and rising demand for contrast and delivery—need reliable partners. Hear Bayer leads explain how Bayer helps provide steady supply and innovations to support CT imaging and patient care.

Routine IR procedure could treat endometriosis.

New oral contrast agent helps spot 'previously impossible-to-detect' findings on CT

Experts involved in its development are confident the agent has the potential to overcome shortcomings associated with conventional oral agents currently on the market.

Prominent organizations endorse new contrast-enhanced ultrasound curriculum and training

The endorsement follows recent program updates, implemented following an expansion to the Scope of Practice and Clinical Standards for the Diagnostic Medical Sonographer.

New iron-based imaging agent significantly improves brain tumor visualization

Ferumoxytol is used primarily in medications that treat anemia, but the FDA recently cleared it for deployment in brain imaging as well.

New data on GBCA safety indicate risk of renal complications 'exceedingly low'

Nephrogenic systemic fibrosis is a serious, potentially fatal disease that progressively causes the skin and underlying tissues to harden.

Dual-energy CT systems allow for significant reduction in contrast dose

DECT systems allow for a contrast dose reduction of up to 25% during computed tomography pulmonary angiography exams.

Experts call for more judicious use of contrast, highlighting environmental concerns

New data highlight the significant burden contrast media use places on the environment, prompting experts to call for more stringent use of these agents.